NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

地圖狀萎縮 (GA):開發平台分析 (2020年)

Geographic Atrophy (GA) - Pipeline Insights, 2020

出版商 DelveInsight Business Research LLP 商品編碼 945501
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 10個工作天內
價格
地圖狀萎縮 (GA):開發平台分析 (2020年) Geographic Atrophy (GA) - Pipeline Insights, 2020
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

地理萎縮症(GA)的原因查明對新治療藥的開發有所貢獻。由於對疾病的認識高漲,及全球性醫療費的增加趨勢,預計今後數年改變GA的市場。

本報告提供地理萎縮症(GA)治療藥的開發平台趨勢調查,疾病概要,目前治療模式,治療指南,R&D的企業間的聯盟等趨勢,產品類型、階段、分子類型、標的等各種區分的開發平台趨勢,未滿足需求,未來展望等資訊。

第1章 簡介

第2章 地理萎縮(GA)

  • 概況
  • 過程
  • 症狀
  • 原因
  • 病理生理學
  • 診斷
    • 診斷指南

第3章 目前治療模式

  • 治療指南

第4章 DelveInsight分析

  • 詳細的商業性評估
    • 交易趨勢:企業合作、授權、收購
    • 聯盟契約

第5章 治療藥的評估

  • 開發平台藥物臨床評估
    • 各開發階段
    • 各產品類型(單劑、並用劑)
    • 各給藥途徑
    • 各分子類型
    • 各MOA評估
    • 各標的

第6章 開發後期的產品(階段III)

第7章 開發中期的產品(階段II)

第8章 開發初期的產品(階段I)

第9章 前臨床、藥物研發階段的產品

第10章 沒改變的產品

第11章 開發休止的產品

第12章 開發中止的產品

第13章 產品簡介

第14章 主要企業

第15章 主要產品

第16章 開發休止、中止的產品

第17章 未滿足需求

第18章 未來展望

第19章 分析師的見解

第20章 附錄

第21章 調查手法

目錄

Overview

"Geographic Atrophy (GA) Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Geographic Atrophy (GA) market. A detailed picture of the Geographic Atrophy (GA) pipeline landscape is provided, which includes the disease overview and Geographic Atrophy (GA) treatment guidelines. The assessment part of the report embraces in-depth Geographic Atrophy (GA) commercial assessment and clinical assessment of the Geographic Atrophy (GA) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Geographic Atrophy (GA) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Geographic Atrophy (GA) of pipeline development activities

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of Geographic Atrophy (GA) with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Geographic Atrophy (GA) treatment.
  • Geographic Atrophy (GA) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Geographic Atrophy (GA) market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Geographic Atrophy (GA) Analytical Perspective by DelveInsight

In-depth Geographic Atrophy (GA) Commercial Assessment of products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Geographic Atrophy (GA) Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

  • The Geographic Atrophy (GA) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Geographic Atrophy (GA) across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Geographic Atrophy (GA) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Geographic Atrophy (GA) research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Geographic Atrophy (GA) .

Report highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Geographic Atrophy (GA) .
  • In the coming years, the Geographic Atrophy (GA) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Geographic Atrophy (GA) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Geographic Atrophy (GA) treatment market. Several potential therapies for Geographic Atrophy (GA) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Geographic Atrophy (GA) market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Geographic Atrophy (GA) ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions

  • What are the current options for Geographic Atrophy (GA) treatment?
  • How many companies are developing therapies for the treatment of Geographic Atrophy (GA) ?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Geographic Atrophy (GA) ?
  • How many Geographic Atrophy (GA) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Geographic Atrophy (GA) ?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Geographic Atrophy (GA) market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Geographic Atrophy (GA) ?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Geographic Atrophy (GA) therapies?
  • What are the clinical studies going on for Geographic Atrophy (GA) and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Geographic Atrophy (GA) ?
  • How many patents are granted and pending for the emerging therapies for the treatment of Geographic Atrophy (GA) ?

Table of Contents

1. Report Introduction

2. Geographic Atrophy (GA)

  • 2.1. Overview
  • 2.2. History
  • 2.3. Geographic Atrophy (GA) Symptoms
  • 2.4. Causes
  • 2.5.Pathophysiology
  • 2.6. Geographic Atrophy (GA) Diagnosis
    • 2.6.1. Diagnostic Guidelines

3. Geographic Atrophy (GA) Current Treatment Patterns

  • 3.1. Geographic Atrophy (GA) Treatment Guidelines

4. Geographic Atrophy (GA) - DelveInsight's Analytical Perspective

  • 4.1. In-depth Commercial Assessment
    • 4.1.1. Geographic Atrophy (GA) companies collaborations, Licensing, Acquisition -Deal Value Trends
      • 4.1.1.1. Assessment Summary
    • 4.1.2. Geographic Atrophy (GA) Collaboration Deals
      • 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
      • 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
      • 4.1.2.3. Geographic Atrophy (GA) Acquisition Analysis

5. Therapeutic Assessment

  • 5.1. Clinical Assessment of Pipeline Drugs
    • 5.1.1. Assessment by Phase of Development
    • 5.1.2. Assessment by Product Type (Mono / Combination)
      • 5.1.2.1. Assessment by Stage and Product Type
    • 5.1.3. Assessment by Route of Administration
      • 5.1.3.1. Assessment by Stage and Route of Administration
    • 5.1.4. Assessment by Molecule Type
      • 5.1.4.1. Assessment by Stage and Molecule Type
    • 5.1.5. Assessment by MOA
      • 5.1.5.1. Assessment by Stage and MOA
    • 5.1.6. Assessment by Target
      • 5.1.6.1. Assessment by Stage and Target

6. Geographic Atrophy (GA) Late Stage Products (Phase-III)

7. Geographic Atrophy (GA) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Geographic Atrophy (GA) Discontinued Products

13. Geographic Atrophy (GA) Product Profiles

  • 13.1. Drug Name: Company
    • 13.1.1. Product Description
      • 13.1.1.1. Product Overview
      • 13.1.1.2. Mechanism of action
    • 13.1.2. Research and Development
      • 13.1.2.1. Clinical Studies
    • 13.1.3. Product Development Activities
      • 13.1.3.1. Collaboration
      • 13.1.3.2. Agreements
      • 13.1.3.3. Acquisition
      • 13.1.3.4. Patent Detail
    • 13.1.4. Tabulated Product Summary
      • 13.1.4.1. General Description Table

Detailed information in the report?

14. Geographic Atrophy (GA) Key Companies

15. Geographic Atrophy (GA) Key Products

  • 16. Dormant and Discontinued Products
    • 16.1. Dormant Products
      • 16.1.1. Reasons for being dormant
    • 16.2. Discontinued Products
      • 16.2.1. Reasons for the discontinuation

17. Geographic Atrophy (GA) Unmet Needs

18. Geographic Atrophy (GA) Future Perspectives

19. Geographic Atrophy (GA) Analyst Review

20. Appendix

21. Report Methodology

  • 21.1. Secondary Research
  • 21.2. Expert Panel Validation

List of Tables

  • Table 1: Geographic Atrophy (GA) Diagnostic Guidelines
  • Table 2: Geographic Atrophy (GA) Treatment Guidelines
  • Table 3: Assessment Summary
  • Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
  • Table 5: Geographic Atrophy (GA) Acquisition Analysis
  • Table 6: Assessment by Phase of Development
  • Table 7: Assessment by Product Type (Mono / Combination)
  • Table 8: Assessment by Stage and Product Type
  • Table 9: Assessment by Route of Administration
  • Table 10: Assessment by Stage and Route of Administration
  • Table 11: Assessment by Molecule Type
  • Table 12: Assessment by Stage and Molecule Type
  • Table 13: Assessment by MOA
  • Table 14: Assessment by Stage and MOA
  • Table 15: Assessment by Target
  • Table 16: Assessment by Stage and Target
  • Table 17: Geographic Atrophy (GA) Late Stage Products (Phase-III)
  • Table 18: Geographic Atrophy (GA) Mid Stage Products (Phase-II)
  • Table 19: Geographic Atrophy (GA) Early Stage Products (Phase-I)
  • Table 20: Pre-clinical and Discovery Stage Products
  • Table 21: Inactive Products
  • Table 22: Dormant Products
  • Table 23: Discontinued Products

List of Figures

  • Figure 1: Disease Overview
  • Figure 2: History
  • Figure 3: Symptoms
  • Figure 4: Causes
  • Figure 5: Pathophysiology
  • Figure 6: Diagnostic Guidelines
  • Figure 7: Treatment Guidelines
  • Figure 8: Geographic Atrophy (GA) companies collaborations, Licensing, Acquisition -Deal Value Trends
  • Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
  • Figure 10: Geographic Atrophy (GA) Acquisition Analysis
  • Figure 11: Assessment by Phase of Development
  • Figure 12: Assessment by Product Type (Mono / Combination)
  • Figure 13: Assessment by Stage and Product Type
  • Figure 14: Assessment by Route of Administration
  • Figure 15: Assessment by Stage and Route of Administration
  • Figure 16: Assessment by Molecule Type
  • Figure 17: Assessment by Stage and Molecule Type
  • Figure 18: Assessment by MOA
  • Figure 19: Assessment by Stage and MOA
  • Figure 20: Late Stage Products (Phase-III)
  • Figure 21: Mid Stage Products (Phase-II)
  • Figure 22: Early Stage Products (Phase-I)
  • Figure 23: Pre-clinical and Discovery Stage Products
  • Figure 24: Inactive Products
  • Figure 25: Dormant Products
  • Figure 26: Discontinued Products
  • Figure 27: Unmet Needs